申请人:Tibotec Pharmaceuticals, Ltd.
公开号:US07595408B2
公开(公告)日:2009-09-29
The present invention relates to methods for the preparation of diastereomerically pure (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol as well as a novel intermediate, (3aR,4S,6aS) 4-methoxy-tetrahydro-furo[3,4-b]furan-2-one for use in said methods. More in particular the invention relates to a stereoselective method for the preparation of diastereomerically pure (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol, as well as methods for the crystallization of (3aR,4S,6aS) 4-methoxy-tetrahydro-furo[3,4-b]furan-2-one and for the epimerization of (3aR,4R,6aS) 4-methoxy-tetrahydro-furo[3,4-b]-furan-2-one to (3aR,4S,6aS) 4-methoxy-tetrahydro-furo[3,4-b]furan-2-one.
本发明涉及一种制备对映异构体纯度高的(3R,3aS,6aR)六氢呋喃[2,3-b]呋喃-3-醇的方法,以及一种新的中间体(3aR,4S,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮用于该方法。更具体地,本发明涉及一种立体选择性的方法,用于制备对映异构体纯度高的(3R,3aS,6aR)六氢呋喃[2,3-b]呋喃-3-醇,以及用于结晶(3aR,4S,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮的方法和将(3aR,4R,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮对映异构体转化为(3aR,4S,6aS)4-甲氧基四氢呋喃[3,4-b]呋喃-2-酮的方法。